Recent Therapeutic Improvements in Pediatric Oncology: One Fellow Generation (2020–2025)
- 1Fellowship Program, Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Barcelona, Spain
- 2Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Barcelona, Spain
- 3Pharmacy, Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Barcelona, Spain
Abstract
Recent therapeutic advances have significantly transformed the management of selected pediatric malignancies. We conducted a narrative review of recently approved therapies with demonstrated clinical impact in pediatric oncology. Evidence from pivotal clinical trials was integrated with real-world experience at the Pediatric Cancer Center Barcelona (PCCB). Fifty-three new oncological drugs with pediatric indication were available in 2025 that were not in routine clinical practice in 2020. We reviewed 18, those available at the PCCB, to demonstrate their meaningful clinical activity, the improved disease control and favorable toxicity profiles. Overall, 688 patients have benefited from these new agents. Real-world experience supports their feasibility and clinical benefit in many pediatric cancers. We realized that a significant number of novel therapies have been approved in the last 5 years and represent an important step toward precision oncology in pediatric cancer. Their integration into clinical practice is reshaping treatment paradigms and offering real opportunities for patients with otherwise limited options. Ongoing studies will define their long-term impact, optimal sequencing, and role within multimodal treatment strategies.
Related
- Ethical dilemmas and intervention strategies in doctor-patient-family communication in end-of-life pediatric oncology: a narrative review
- Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models
- Digital 3D Technology in Pediatric Surgical Oncology: An Expert White Paper
- Transfusion practices, thresholds, and complications in pediatric oncology patients: a single-center prospective longitudinal observational study
- Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis
BibTeX
@article{quinterogarcia2026recent,
title = {{Recent Therapeutic Improvements in Pediatric Oncology: One Fellow Generation (2020–2025)}},
author = {Diannet Quintero-García and Aina Seguí and Andrea G. Palau and Alicia Pablos and Mariona Nadal and Ana I. Vega and Itziar Bueno and Miriam Dacil Cañada and Raquel P. Suarez and María Iriondo and Martín Cueto and Maite Gorostegui and Alicia Castañeda and María Muñoz and Ivan Prieto and Veronica Celis and Paula Mazorra and Juan P. Muñoz and Ainhoa Lasarte and Marina Caballero-Bellón and Cristina Larrosa and Jaume Mora},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213447},
url = {https://www.mdpi.com/2072-6694/18/21/3447},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Recent Therapeutic Improvements in Pediatric Oncology: One Fellow Generation (2020–2025)
AU - Diannet Quintero-García
AU - Aina Seguí
AU - Andrea G. Palau
AU - Alicia Pablos
AU - Mariona Nadal
AU - Ana I. Vega
AU - Itziar Bueno
AU - Miriam Dacil Cañada
AU - Raquel P. Suarez
AU - María Iriondo
AU - Martín Cueto
AU - Maite Gorostegui
AU - Alicia Castañeda
AU - María Muñoz
AU - Ivan Prieto
AU - Veronica Celis
AU - Paula Mazorra
AU - Juan P. Muñoz
AU - Ainhoa Lasarte
AU - Marina Caballero-Bellón
AU - Cristina Larrosa
AU - Jaume Mora
PY - 2026
DA - 2026/10/25
JO - Cancers
DO - 10.3390/cancers18213447
UR - https://www.mdpi.com/2072-6694/18/21/3447
AB - Recent therapeutic advances have significantly transformed the management of selected pediatric malignancies. We conducted a narrative review of recently approved therapies with demonstrated clinical impact in pediatric oncology. Evidence from pivotal clinical trials was integrated with real-world experience at the Pediatric Cancer Center Barcelona (PCCB). Fifty-three new oncological drugs with pediatric indication were available in 2025 that were not in routine clinical practice in 2020. We reviewed 18, those available at the PCCB, to demonstrate their meaningful clinical activity, the improved disease control and favorable toxicity profiles. Overall, 688 patients have benefited from these new agents. Real-world experience supports their feasibility and clinical benefit in many pediatric cancers. We realized that a significant number of novel therapies have been approved in the last 5 years and represent an important step toward precision oncology in pediatric cancer. Their integration into clinical practice is reshaping treatment paradigms and offering real opportunities for patients with otherwise limited options. Ongoing studies will define their long-term impact, optimal sequencing, and role within multimodal treatment strategies.
SN - 2072-6694
ER -